Robust data you can trust

For most researchers, robustness shows up over time, when a technology produces consistent results day in, day out across tricky sample types and growing datasets. It’s about being able to trust the workflows even when inputs aren’t perfect or conditions aren’t predictable.

When data generation is robust, confidence follows. Researchers don’t have to second-guess whether a result reflects underlying biology or technical variability. Instead, they can rely on their sequencing data to be consistent and reproducible, freeing them to move faster and make decisions backed by evidence they trust.

In this Real Talk with Researchers blog, we hear from scientists using our technology in demanding research environments, sharing how consistent, reliable data generation has become a given — allowing them to focus on the questions that matter most.

Martin Wendlandt: analysing large datasets with confidence

For researchers at the Medical Genetics Center (MGZ) in Munich (Germany), Martin notes that Oxford Nanopore technology gives them all the data they require — in one go. Their method provides accurate sequencing data at scale, meaning the team can spend less time at the bench and more time analysing what the data is telling them.

Lucia Clemens-Daxinger: delivering robust data for powerful insights

Lucia uses nanopore sequencing to study DNA methylation and histone modifications as part of her developmental epigenetics research. Our technology provides methylation information at single-nucleotide resolution, allowing Lucia to get robust data she can rely on.

Nate Edisis: a reliable base for rare disease research

On the long journey to characterise rare diseases, samples aren’t always fresh and researchers often have to work with whatever material is available. At Boston Children’s Hospital (USA), Nate finds that nanopore sequencing is reliable on old samples as well as new. That consistency matters when you’re trying to piece together answers to questions that have been unsolved for years, and could one day help end the diagnostic odysseys faced by patients and families.

Barnaby Clark: multidimensional insights from a single assay

Nanopore sequencing shows potential to replace the 'battery of tests’ currently used for clinical testing at King’s College Hospital (UK), according to Barnaby. Our technology provides the team with data on methylation, single nucleotide polymorphisms (SNPs), copy number variation, and fusion calling — in one go. Seeing these multiple layers of information at once opens the door to rapid tumour classification, and, in the future, more targeted treatment decisions.

Mike Hubank: rapid delivery of results you can trust

The NHS is often challenged by long turnaround times and budget constraints, and The Royal Marsden Hospital (UK) is no exception. Mike explains that nanopore sequencing shows clear potential to help address these pressures. Getting the right results faster could eliminate the need for further downstream interventions, saving the NHS time and money, and ultimately improving patient outcomes in the future.

Alimat Oyawoye and Tilda Tierney: high-quality data from low-quality samples

As part of the NIHR BioResource 22,000 genomes project, Alimat and Tilda needed to find a sequencing protocol they could trust to be reproducible across multiple sample types and different sites. Nanopore sequencing provides them with robust datasets that are comparable between labs, even from low-quality saliva samples.

Curious to learn more? Find out how you can gain accurate, multidimensional insights — in one go.

If you enjoyed this blog, check out another in our Real Talk with Researchers series: scalability without compromise

Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.